Investors

Retired Chairman of the Board and Chief Executive Officer, Merck & Co. Inc.

P. Roy Vagelos, MD, has been Chairman of the Board of the Company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010.

Retired Chairman of the Board, President and Chief Executive Officer of The Liposome Company, Inc.

Charles A. Baker has been a Director of the Company since February 1989. In September 2000, Mr. Baker retired as Chairman, President, and Chief Executive Officer of The Liposome Company, Inc., a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various pharmaceutical companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb) and President, Squibb International, and various senior executive positions at Abbott Laboratories and Pfizer, Inc. Mr. Baker currently is a member of the Board of Directors of Progenics Pharmaceuticals, Inc.

Michael S. Brown, MD

Regental Professor of Molecular Genetics and Internal Medicine,
Director, Jonsson Center for Molecular Genetics
The University of Texas Southwestern Medical Center at Dallas

Michael S. Brown, M.D., has been a Director of the Company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Dr. Brown served as a member of the Board of Directors of Pfizer, Inc until April 2012.

Regental Professor of Pharmacology Emeritus
The University of Texas Southwestern Medical Center at Dallas

Alfred G. Gilman, M.D., Ph.D., a co-founder of the Company, has been Director of the Company since July 1990. Dr. Gilman, formerly Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas (from 2009-2012), is a Regental Professor of Pharmacology Emeritus at The University of Texas Southwestern Medical Center at Dallas. He previously served as executive vice president for academic affairs and provost of the University of Texas Southwestern Medical Center at Dallas, dean of the University of Texas Southwestern Medical School, and professor of pharmacology at The University of Texas Southwestern Medical Center. Dr. Gilman is a member of the National Academy of Sciences, and he received the Nobel Prize for Physiology or Medicine in 1994. Dr. Gilman is a member of the Board of Directors of Eli Lilly & Company

Joseph L. Goldstein, MD

Regental Professor and Chairman, Department of Molecular Genetics The University of Texas Southwestern Center at Dallas

Joseph L. Goldstein, MD, has been a Director of the Company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.

Dean and John W. Berry, Sr. Chair in Business at the Max M. Fisher College of Business at The Ohio State University

Christine A. Poon has been a director of the Company since 2010. Ms. Poon is Dean and the John W. Berry, Sr. Chair in Business at The Max M. Fisher College of Business at The Ohio State University, a position she has held since 2009. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004 and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.

Arthur F. Ryan

Retired Chairman of the Board and Chief Executive Officer Prudential Financial, Inc.

Arthur F. Ryan has been a Director of the Company since January 2003. In 2008 Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Prior to joining Prudential in December 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan ran Chase’s worldwide retail bank between 1984 and 1990. Mr. Ryan is a non-executive director of the Royal Bank of Scotland Group plc.

President and Chief Executive Officer

Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. From 1984 to 1988 he was Assistant Professor at Cornell University Medical College in the Departments of Neurology and Neurobiology. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.

Eric M. Shooter, PhD

Professor Emeritus, Department of Neurobiology Stanford University School of Medicine

Eric M. Shooter, PhD, a co-founder of the Company, has been a Director since 1988. Dr. Shooter has been a Professor at Stanford University School of Medicine since 1968 and is now a Professor Emeritus. He was the founding Chairman of the Department of Neurobiology at Stanford University School of Medicine in 1975 and served as its Chairman until 1987. Dr. Shooter is a Fellow of the Royal Society of England and a member of the National Academy of Sciences.

Cheif Executive Officer, Stemnion, Inc.
Managing Director, Lancet Capital

George L. Sing has been a Director of the Company since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Since January 2004, Mr Sing has served as Chief Executive Officer of Stemnion, Inc., a bio-medical company in the regenerative medicine field.

Marc Tessier-Lavigne PhD

President, The Rockefeller University

Marc Tessier-Lavigne, PhD., has been a Director of the Company since November 2011. Dr. Tessier-Lavigne was appointed President of The Rockefeller University in 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada.

Founding Scientist, President, Regeneron Laboratories & Chief Scientific Officer

George D. Yancopoulos, M.D., Ph.D., has been President, Regeneron Laboratories and Chief Scientific Officer since December 2000 and a Director since 2001. Prior to that date, he was Senior Vice President, Research, a position he held since June 1997, and Chief Scientific Officer, a position he held since January 1998. Dr. Yancopoulos was Vice President Discovery from January 1992 until June 1997, and Head of Discovery from January 1991 to January 1992. He joined Regeneron in March 1989 as its founding scientist. He received his Ph.D. in Biochemistry and Molecular Biophysics and his M.D. from Columbia University. Dr. Yancopoulos is a member of the National Academy of Sciences.

	Audit	Compensation	Corporate Governance and Compliance	Technology
P. Roy Vagelos, MD
Retired Chairman of the Board and Chief Executive Officer, Merck & Co. Inc. P. Roy Vagelos, MD, has been Chairman of the Board of the Company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010.
Charles A. Baker
Retired Chairman of the Board, President and Chief Executive Officer of The Liposome Company, Inc. Charles A. Baker has been a Director of the Company since February 1989. In September 2000, Mr. Baker retired as Chairman, President, and Chief Executive Officer of The Liposome Company, Inc., a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various pharmaceutical companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb) and President, Squibb International, and various senior executive positions at Abbott Laboratories and Pfizer, Inc. Mr. Baker currently is a member of the Board of Directors of Progenics Pharmaceuticals, Inc.
Michael S. Brown, MD
Regental Professor of Molecular Genetics and Internal Medicine, Director, Jonsson Center for Molecular Genetics The University of Texas Southwestern Medical Center at Dallas Michael S. Brown, M.D., has been a Director of the Company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Dr. Brown served as a member of the Board of Directors of Pfizer, Inc until April 2012.
Alfred G. Gilman, M.D., Ph.D.
Regental Professor of Pharmacology Emeritus The University of Texas Southwestern Medical Center at Dallas Alfred G. Gilman, M.D., Ph.D., a co-founder of the Company, has been Director of the Company since July 1990. Dr. Gilman, formerly Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas (from 2009-2012), is a Regental Professor of Pharmacology Emeritus at The University of Texas Southwestern Medical Center at Dallas. He previously served as executive vice president for academic affairs and provost of the University of Texas Southwestern Medical Center at Dallas, dean of the University of Texas Southwestern Medical School, and professor of pharmacology at The University of Texas Southwestern Medical Center. Dr. Gilman is a member of the National Academy of Sciences, and he received the Nobel Prize for Physiology or Medicine in 1994. Dr. Gilman is a member of the Board of Directors of Eli Lilly & Company
Joseph L. Goldstein, MD
Regental Professor and Chairman, Department of Molecular Genetics The University of Texas Southwestern Center at Dallas Joseph L. Goldstein, MD, has been a Director of the Company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.
Christine A. Poon
Dean and John W. Berry, Sr. Chair in Business at the Max M. Fisher College of Business at The Ohio State University Christine A. Poon has been a director of the Company since 2010. Ms. Poon is Dean and the John W. Berry, Sr. Chair in Business at The Max M. Fisher College of Business at The Ohio State University, a position she has held since 2009. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004 and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.
Arthur F. Ryan
Retired Chairman of the Board and Chief Executive Officer Prudential Financial, Inc. Arthur F. Ryan has been a Director of the Company since January 2003. In 2008 Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Prior to joining Prudential in December 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan ran Chase’s worldwide retail bank between 1984 and 1990. Mr. Ryan is a non-executive director of the Royal Bank of Scotland Group plc.
Leonard S. Schleifer, M.D., Ph.D.
President and Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. From 1984 to 1988 he was Assistant Professor at Cornell University Medical College in the Departments of Neurology and Neurobiology. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.
Eric M. Shooter, PhD
Professor Emeritus, Department of Neurobiology Stanford University School of Medicine Eric M. Shooter, PhD, a co-founder of the Company, has been a Director since 1988. Dr. Shooter has been a Professor at Stanford University School of Medicine since 1968 and is now a Professor Emeritus. He was the founding Chairman of the Department of Neurobiology at Stanford University School of Medicine in 1975 and served as its Chairman until 1987. Dr. Shooter is a Fellow of the Royal Society of England and a member of the National Academy of Sciences.
George L. Sing
Cheif Executive Officer, Stemnion, Inc. Managing Director, Lancet Capital George L. Sing has been a Director of the Company since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Since January 2004, Mr Sing has served as Chief Executive Officer of Stemnion, Inc., a bio-medical company in the regenerative medicine field.
Marc Tessier-Lavigne PhD
President, The Rockefeller University Marc Tessier-Lavigne, PhD., has been a Director of the Company since November 2011. Dr. Tessier-Lavigne was appointed President of The Rockefeller University in 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada.
George D. Yancopoulos, M.D., Ph.D.
Founding Scientist, President, Regeneron Laboratories & Chief Scientific Officer George D. Yancopoulos, M.D., Ph.D., has been President, Regeneron Laboratories and Chief Scientific Officer since December 2000 and a Director since 2001. Prior to that date, he was Senior Vice President, Research, a position he held since June 1997, and Chief Scientific Officer, a position he held since January 1998. Dr. Yancopoulos was Vice President Discovery from January 1992 until June 1997, and Head of Discovery from January 1991 to January 1992. He joined Regeneron in March 1989 as its founding scientist. He received his Ph.D. in Biochemistry and Molecular Biophysics and his M.D. from Columbia University. Dr. Yancopoulos is a member of the National Academy of Sciences.

Investors

Committee Composition